Pereira C, Sousa H, Ferreira P, Fragoso M, Moreira-Dias L, Lopes C, Medeiros R, Dinis-Ribeiro M. -765G > C COX-2 polymorphism may be a susceptibility marker for gastric adenocarcinoma in patients with atrophy or intestinal metaplasia. World J Gastroenterol 2006; 12(34): 5473-5478 [PMID: 17006983 DOI: 10.3748/wjg.v12.i34.5473]
Corresponding Author of This Article
Mário Dinis-Ribeiro, MD, PhD, Serviço de Gastrenterologia, Instituto Português de Oncologia do Porto FG EPE, Rua Dr. António Bernardino Almeida, 4200-072 Porto, Portugal. mario@med.up.pt
Article-Type of This Article
research-article
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Pereira C, Sousa H, Ferreira P, Fragoso M, Moreira-Dias L, Lopes C, Medeiros R, Dinis-Ribeiro M. -765G > C COX-2 polymorphism may be a susceptibility marker for gastric adenocarcinoma in patients with atrophy or intestinal metaplasia. World J Gastroenterol 2006; 12(34): 5473-5478 [PMID: 17006983 DOI: 10.3748/wjg.v12.i34.5473]
World J Gastroenterol. Sep 14, 2006; 12(34): 5473-5478 Published online Sep 14, 2006. doi: 10.3748/wjg.v12.i34.5473
-765G > C COX-2 polymorphism may be a susceptibility marker for gastric adenocarcinoma in patients with atrophy or intestinal metaplasia
Mário Dinis-Ribeiro, Rui Medeiros, Carlos Lopes, Luís Moreira-Dias, Maria Fragoso, Paula Ferreira, Hugo Sousa, Carina Pereira
Carina Pereira, Paula Ferreira, Molecular Oncology Group, Portuguese Institute of Oncology of Porto, Portugal
Maria Fragoso, Oncology Department, Portuguese Institute of Oncology of Porto, Portugal
Luís Moreira-Dias, Gastroenterology Department, Portuguese Institute of Oncology of Porto, Portugal
Hugo Sousa, Carlos Lopes, Rui Medeiros, Molecular Oncology Group, Portuguese Institute of Oncology of Porto, Portugal; and ICBAS, Abel Salazar Institute for the Biomedical Sciences, Porto, Portugal
Mário Dinis-Ribeiro, Gastroenterology Department, Portuguese Institute of Oncology of Porto, Portugal; and Cintesis / Faculty of Medicine University of Porto, Porto, Portugal
Supported by the Portuguese League Against Cancer (Liga Portuguesa Contra o Cancro-Núcleo Regional do Norte) and AstraZeneca Foundation
Correspondence to: Mário Dinis-Ribeiro, MD, PhD, Serviço de Gastrenterologia, Instituto Português de Oncologia do Porto FG EPE, Rua Dr. António Bernardino Almeida, 4200-072 Porto, Portugal. mario@med.up.pt
Received: May 12, 2006 Revised: May 28, 2006 Accepted: June 16, 2006 Published online: September 14, 2006
Abstract
AIM: To investigate the relationship between the -765G > C COX-2 polymorphism and the development of different gastric lesions: atrophy or intestinal metaplasia and gastric adenocarcinoma.
METHODS: A cross-sectional study was performed involving 320 Portuguese individuals (210 without evidence of neoplastic disease, 73 patients with gastric adenocarcinomas and 37 with atrophy or intestinal metaplasia) using a PCR-RFLP method.
RESULTS: -765C allele was overrepresented in the patients with gastric adenocarcinoma (51%) when compared either with the control group (38%) or patients with atrophy or intestinal metaplasia (27%). Callele was found to be very common in our population (0.22), and a multivariate logistic regression analysis revealed nearly 3-fold increased risk for the progression to gastric adenocarcinoma in patients with atrophy or intestinal metaplasia carrying the -765C allele (OR = 2.67, 95% CI = 1.03-6.93; P = 0.04).
CONCLUSION: -765C carrier status should be considered as another susceptibility marker for gastric adenocarcinoma development in patients with atrophy or intestinal metaplasia.
